Less than 1 min.Read

Transcenta: Completes $105M Crossover Financing

December 28, 2020

Transcenta Holding Limited, a global biotherapeutics company with integrated capabilities in discovery, completed a 105m USD crossover financing
China Structural Reform Fund led the financing round, participated by new investors
Existing investors including CCT China Merchants Fund, Lilly Asia Ventures, Teng Yue Partners, Sequoia Capital China, and others also participated in this round
The proceeds from new funding will used to accelerate ongoing clinical programs and prepare for commercialization
Transcenta is a global biotherapeutics company that fully integrates antibody-based biotherapeutics discovery, development, and manufacturing
In 2020, TST001, a CLDN18.2 targeting antibody and one of its leading programs, has been moving quickly in a clinic in both US and China